Inovio Wins FDA Accelerated Approval for VOCERYQ to Reduce RRP Surgery

What happened

Inovio received FDA accelerated approval for VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. Approval relied on complete response data: 7 of 26 patients, or 27%, needed no surgery during the 12 months after treatment. The treatment is used with Inovio’s CELLECTRA 5PSP device.

Confirmed

Global impact / market context

The approval gives Inovio a path to sell VOCERYQ, with ordering and shipping expected in about 60 days and full field deployment anticipated in the first quarter of 2027. If patients adopt the treatment, product sales could add revenue, while required follow-up evidence creates a risk that continued approval may not be assured.

Analyst inference

This is an approval milestone, but the evidence described is limited: 7 of 26 patients avoided surgery for 12 months. The FDA requires Inovio to submit a draft study protocol by year-end 2026 and align on a final protocol by mid-2027 to confirm clinical benefit.

Confirmed

What to watch

1. Whether VOCERYQ becomes available to order and ship in about 60 days, as expected; delays could push back the timing of potential product revenue. Confirmed
2. Whether Inovio submits the required draft study protocol by year-end 2026 and reaches final-protocol alignment with the FDA by mid-2027. Confirmed
3. Whether later study results confirm clinical benefit; failure to do so could put continued approval at risk and weaken the treatment’s commercial prospects. Analyst inference

Evidence

• Original source link unavailable